Skip to the content

pharmaceutical daily

Pharmaceuticals, Biotechnology and Life Sciences

  • HOME
  • Pharma Business
  • About us
    • Media Kit
    • Privacy Policy
  • Contact
ObsEva kicks off third phase of testing its nolasiban for backing up pregnancy rates and live births for in-vitro fertilization
November 28, 2018 Off

ObsEva kicks off third phase of testing its nolasiban for backing up pregnancy rates and live births for in-vitro fertilization

By Dino Mustafić

ObsEva SA has started testing in third phase its oral oxytocin receptor antagonist, nolasiban, for the improvement of rates of pregnancy and live birth in patients undergoing assisted reproduction technology (ART), or in-vitro fertilization (IVF).

Alcon spinoffs from Novartis in first half of 2019
November 27, 2018 Off

Alcon spinoffs from Novartis in first half of 2019

By Dino Mustafić

Novartis’s eye care division Alcon, on Tuesday has its first Capital Markets Day for investors and analysts as a tax-neutral,…

ADC Therapeutics dosed first patients clinically testing its drug in relapsed or refractory B-cell Acute Lymphoblastic Leukemia
November 27, 2018 Off

ADC Therapeutics dosed first patients clinically testing its drug in relapsed or refractory B-cell Acute Lymphoblastic Leukemia

By Dino Mustafić

ADC Therapeutics has dosed the first patients with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL), in a Phase I/II…

Germany company Adrenomed raises €24 million to push Adrecizumab’s clinical trial
November 27, 2018 Off

Germany company Adrenomed raises €24 million to push Adrecizumab’s clinical trial

By Dino Mustafić

German privately financed vascular integrity company Adrenomed has closed a €24 million series D financing round co-led by Wellington Partners…

Julca Combination approved in Japan for treating HIV
November 27, 2018 Off

Julca Combination approved in Japan for treating HIV

By Dino Mustafić

ViiV Healthcare and Janssen Sciences Ireland UC’s Juluca Combination Tablets for treating HIV (type 1) was approved by the Ministry…

Sandoz gets marketing pass in EU for Ziextenzo, for helping treat cancer with cytotoxic chemotherapy in adults
November 27, 2018 Off

Sandoz gets marketing pass in EU for Ziextenzo, for helping treat cancer with cytotoxic chemotherapy in adults

By Dino Mustafić

Novartis’ Sandoz, received on Tuesday from the European Commission (EC) the marketing authorization for biosimilar Ziextenzo (pegfilgrastim), which is indicated to reduce the…

EU approves Novartis’ the one-time gene therapy Luxturna
November 23, 2018 Off

EU approves Novartis’ the one-time gene therapy Luxturna

By Dino Mustafić

Novartis’ Luxturna, a one-time gene therapy for the treatment of patients with vision loss due to a genetic mutation, developed…

Curetis nears clearing BAL as additional sample type for Unyvero LRT
November 23, 2018 Off

Curetis nears clearing BAL as additional sample type for Unyvero LRT

By Dino Mustafić

The U.S. FDA confirmed that data required for the submission can largely be based on clinical samples previously collected during…

Oasmia’s Apalea approved in Europe for ovarian cancer
November 22, 2018 Off

Oasmia’s Apalea approved in Europe for ovarian cancer

By Dino Mustafić

After the Oasmia Pharmaceutical’s pivotal study OAS 07OVA conducted on ovarian cancer patients with disease relapse, showed that the risks…

GSK, Kyowa Hakko Kirin mutual work on potential oral treatment for CKD related anaemia
November 22, 2018 Off

GSK, Kyowa Hakko Kirin mutual work on potential oral treatment for CKD related anaemia

By Dino Mustafić

GSK and Kyowa Hakko Kirin will together commercialize in Japan the treatment of chronic kidney disease related anaemina, which GKS…

Posts pagination

Previous 1 … 3,379 3,380 3,381 … 3,606 Next

JOIN OUR COMMUNITY

Proudly powered by WordPress | Theme: Envo Magazine